Press Releases April 29, 2026 11:30 AM

Alexander’s Declares Quarterly $4.50 Dividend on Common Shares

Alexander's, Inc. announces $4.50 quarterly dividend for shareholders.

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
ALX

Alexander's, Inc., a New York City-based real estate investment trust (REIT), declared a $4.50 per share quarterly dividend payable on May 29, 2026, signaling strong financial health and steady income for investors. The announcement highlights the company's ongoing commitment to shareholder returns amid various economic factors including interest rates and inflation.

Alexander’s Declares Quarterly $4.50 Dividend on Common Shares
ALX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Alexander's, Inc. declared a quarterly dividend of $4.50 per share to be paid on May 29, 2026.
  • The company owns five properties located in New York City, emphasizing its focus within the urban real estate market.
  • The announcement includes forward-looking statements addressing risks such as interest rate fluctuations and inflation impacting financial performance.

PARAMUS, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- Alexander’s, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on May 29, 2026 to stockholders of record on May 11, 2026.

Alexander’s, Inc. is a real estate investment trust that has five properties in New York City.

CONTACT:
GARY HANSEN
(201) 587-8541

Certain statements contained herein constitute forward-looking statements as such term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are not guarantees of performance. They represent our intentions, plans, expectations and beliefs and are subject to numerous assumptions, risks and uncertainties. Our future results, financial condition and business may differ materially from those expressed in these forward-looking statements. Many of the factors that will determine the outcome of these and our other forward-looking statements are beyond our ability to control or predict. Currently, some of the factors are interest rate fluctuations and the effects of inflation on our business, financial condition, results of operations, cash flows, operating performance and the effect that these factors have had and may continue to have on our tenants, the global, national, regional and local economies and financial markets and the real estate market in general. For further discussion of factors that could materially affect the outcome of our forward-looking statements, see "Item 1A. Risk Factors" in Part I of our Annual Report on Form 10-K for the year ended December 31, 2025. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All subsequent written and oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.


Risks

  • Interest rate fluctuations could affect the company's borrowing costs and profitability, influencing dividend sustainability, impacting the real estate and financial sectors.
  • Inflation may affect operational costs and tenant financial stability, potentially impacting rental income and performance of the real estate market.
  • Economic conditions at global, national, regional, and local levels could influence real estate demand and market valuations, adding uncertainty to future results.

More from Press Releases

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026